Academic Journal
Q1Cancer Immunology, Immunotherapy
About Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy is a scholarly journal published by Springer Science and Business Media Deutschland GmbH. SCImago 2025 lists it in Q1, with an SJR of 1.805 and H-index of 148.
Coverage: 1976-2026. Research categories: Cancer Research (Q1); Immunology (Q1); Immunology and Allergy (Q1); Medicine (miscellaneous) (Q1); Oncology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Immunotherapy and Immune Responses; Cancer Immunotherapy and Biomarkers; Immune Cell Function and Interaction; CAR-T cell therapy research; T-cell and B-cell Immunology; Monoclonal and Polyclonal Antibodies Research.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
A phase II pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma, with sequential evaluation of the tumor microenvironment
Craig L. Slingluff, Marc S. Ernstoff, David Lawson, Keith A. Delman et al.
2026-10-02 · DOI: 10.1007/s00262-026-04572-zRegulatory B cells and the microbiome: implications for checkpoint blockade therapy in cancer
Akshay J. Patel, Gary W. Middleton
2026-10-02 · DOI: 10.1007/s00262-026-04563-0Transcription factor RBPJ improves the efficacy of PD-1/PD-L1-based therapies in non-small cell lung cancer by expanding CD8+ tissue-resident memory T cells
Gaoming Liao, Qi Liu, Min Zhang, Yan Liu et al.
2026-10-01 · DOI: 10.1007/s00262-026-04571-0Dynamics of peripheral blood NKT cells and PD-L1-expressing classical monocytes as immune correlates of radiotherapy-primed atezolizumab in relapsed small cell lung cancer: a phase II study
Yang-Gun Suh, Youngjoo Lee, Sung Ho Moon, Seojin Lee et al.
2026-10-01 · DOI: 10.1007/s00262-026-04570-1TREM2 blockade reprograms HER2 CAR macrophages toward inflammatory phagocytes in breast cancer models
Jassaud Marius, Ziane-Chaouche Lydia, Raffo-Romero Antonella, Salzet Michel et al.
2026-10-01 · DOI: 10.1007/s00262-026-04576-9Radiotherapy drives PD-1 expression on monocytes to attenuate anti-tumor immunity
Jiandong Zhang, Chen Chen, Qiuyu Mu, Yuzhu Hou et al.
2026-09-29 · DOI: 10.1007/s00262-026-04519-4Seasonal variations in overall survival and vitamin D status in a UK pan-cancer cohort receiving checkpoint inhibitors
Oliver Kennedy, Nadia Ali, Rebecca Lee, Safwaan Adam et al.
2026-09-29 · DOI: 10.1007/s00262-026-04575-wRadiation potentiates natural killer cell therapy combined with Atezolizumab and Bevacizumab in SNU-398 hepatocellular carcinoma models
Ga-Young Park, Woo-Chang Son, Hong-Rae Lee, Hyun Bon Kang et al.
2026-09-29 · DOI: 10.1007/s00262-026-04545-2Porphyromonas gingivalis adhesion protein Mfa1 enhances the anti-cancer effect of anti–PD-L1 antibody by immune activation
Eun-Koung An, Wei Zhang, Minjun Jung, Hae-Bin Park et al.
2026-09-29 · DOI: 10.1007/s00262-026-04587-6Targeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells
Huijian Zheng, Huajian Xian, Chaoqun Lu, Wenjie Zhang et al.
2026-09-27 · DOI: 10.1007/s00262-026-04584-9Efficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trial
Shaolei Li, Xinrun Cui, Dachuan Zhao, Ye Tao et al.
2026-09-27 · DOI: 10.1007/s00262-026-04579-6Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1: mechanistic insights from nasopharyngeal carcinoma and implications for multi-system diseases
Jiaodi Cai, Feng Jiang, Li Xiao, Wenqin Zhang et al.
2026-09-25 · DOI: 10.1007/s00262-026-04580-zAdding nivolumab to definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma: a propensity score matching study
Ming-Wei Kao, Kun-Chou Hsieh, Wen-Lun Wang, Shyh-An Yeh et al.
2026-09-25 · DOI: 10.1007/s00262-026-04552-3Revisiting human circulating γδ T cells: developmental insights and manufacturing challenges for cancer immunotherapy
Jeng-Rong Lin, Lakshay Kapil, Huan-An Tsai, Wen-Chieh Liao et al.
2026-09-24 · DOI: 10.1007/s00262-026-04561-2Decoding macrophage polarization heterogeneity in post-chemotherapy AML microenvironments
Pei Zhu, Wenjuan Zhang, Zhihua Wu, Yuping Deng et al.
2026-09-24 · DOI: 10.1007/s00262-026-04569-8Molecular regulatory network of PD-L1 expression under Helicobacter pylori infection and its clinical translational value: a review of multi-pathway crosstalk mechanisms
Qiwei Wang, Tianjiao Duan, Juju Feng, Linqing Sun et al.
2026-09-23 · DOI: 10.1007/s00262-026-04581-yCYP2S1: a novel regulator of PMN-MDSC recruitment and immunotherapy resistance in esophageal squamous cell carcinoma
Xiaoyan Li, Chunning Li, Xiaoxi Li, Zhengda Li et al.
2026-09-22 · DOI: 10.1007/s00262-026-04556-zA56-anchored IL-15Rα arms a fusogenic oncolytic vaccinia virus to reprogram the tumor microenvironment and enhance antitumor immunity
Mona Alhussein Aboalela, Mohamed Abdelmoneim, Yu Orikono, Shigeru Matsumura et al.
2026-09-21 · DOI: 10.1007/s00262-026-04558-xIdentification of immunodominant ERV peptides critical for anti-metastatic immunity in a model of TNBC
Pouya Faridi, Damien Zanker, Nicole M. Haynes, Joshua Nickson et al.
2026-09-20 · DOI: 10.1007/s00262-026-04554-1Myeloid-derived suppressor cells confer stemness to esophageal cancer cells through the HNF1A/CXCL1 signaling axis
Guohui Qin, Pingchuan Ma, Shasha Liu, Tianran Chen et al.
2026-09-20 · DOI: 10.1007/s00262-026-04577-8Reviews
Community Reviews
Version History
September 25, 2026 at 7:13 am
September 25, 2026